PriceTargets.com logo

Nuvation Bio - NUVB Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $4.00
  • Forecasted Upside: 143.90%
  • Number of Analysts: 6
  • Breakdown:
  • 0 Sell Ratings
  • 3 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$1.64 As of 03/24/2023 01:00 AM ET
▼ -0.02 (-1.20%)

This chart shows the closing price for NUVB by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Nuvation Bio Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for NUVB and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for NUVB

Analyst Price Target is $4.00
▲ +143.90% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for Nuvation Bio in the last 3 months. The average price target is $4.00, with a high forecast of $6.00 and a low forecast of $2.00. The average price target represents a 143.90% upside from the last price of $1.64.

This chart shows the closing price for NUVB for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 6 investment analysts is to buy stock in Nuvation Bio. This rating changed within the last month from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
10/2/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
12/31/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
3/31/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
6/29/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
9/27/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
12/26/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
2/24/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
3/26/2023

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 3 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/24/2023HC WainwrightReiterated RatingBuy$4.50Low
3/16/2023Royal Bank of CanadaReiterated RatingOutperform$6.00Low
3/16/2023WedbushReiterated RatingOutperform$5.00Low
1/6/2023Jefferies Financial GroupDowngradeBuy ➝ Hold$5.00 ➝ $2.00Low
8/22/2022HC WainwrightLower TargetBuy$14.00 ➝ $4.50Low
8/2/2022BMO Capital MarketsDowngradeOutperform ➝ Market Perform$8.00 ➝ $2.50Low
8/2/2022BTIG ResearchDowngradeBuy ➝ NeutralLow
8/1/2022WedbushLower TargetOutperform$17.00 ➝ $5.00Low
5/10/2022WedbushLower TargetOutperform$23.00 ➝ $17.00High
5/4/2022HC WainwrightInitiated CoverageBuy$14.00High
3/22/2022BMO Capital MarketsLower TargetOutperform$17.00 ➝ $12.00Low
3/1/2022WedbushReiterated RatingOutperform$23.00Low
4/6/2021Royal Bank of CanadaInitiated CoverageOutperform$15.00High
3/15/2021BTIG ResearchReiterated RatingBuy$16.00High
3/8/2021Jefferies Financial GroupInitiated CoverageBuy$20.00High
3/8/2021CowenInitiated CoverageOutperformHigh
3/8/2021WedbushInitiated CoverageOutperform$20.00High
3/8/2021BTIG ResearchInitiated CoverageBuy$16.00High
3/8/2021BMO Capital MarketsInitiated CoverageOutperform$16.00High
(Data available from 3/26/2018 forward)

News Sentiment Rating

0.26 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 3 very positive mentions
  • 3 positive mentions
  • 2 negative mentions
  • 2 very negative mentions
Mentions as of
8/28/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/27/2022
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/27/2022
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/26/2022
  • 3 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/26/2022
  • 1 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
1/25/2023
  • 2 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/24/2023
  • 2 very positive mentions
  • 13 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/26/2023

Current Sentiment

  • 2 very positive mentions
  • 13 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Nuvation Bio logo
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-422, a small molecule inhibitor targeting cyclin-dependent kinase (CDK)2, CDK4, and CDK6. It is also developing NUV-868, a selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation; NUV-569, a differentiated oral small molecule selective inhibitor of the Wee1 kinase for DNA damage repair; NUV-1182, an adenosine receptor inhibitor; and drug-drug conjugate (DDC) platform that focuses on targeting an inhibitor of poly ADP ribose polymerase (PARP) to anti-cancer warheads of existing drugs, as well as PARP inhibitor to address ER+ breast and ovarian cancer. The company was formerly known as RePharmation Inc. and changed its name to Nuvation Bio Inc. in April 2019. Nuvation Bio Inc. was founded in 2018 and is headquartered in New York, New York.
Read More

Today's Range

Now: $1.64
Low: $1.62
High: $1.66

50 Day Range

MA: $2.05
Low: $1.60
High: $2.48

52 Week Range

Now: $1.64
Low: $1.55
High: $6.02

Volume

410,039 shs

Average Volume

782,435 shs

Market Capitalization

$358.83 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.66

Frequently Asked Questions

What sell-side analysts currently cover shares of Nuvation Bio?

The following Wall Street research analysts have issued stock ratings on Nuvation Bio in the last twelve months: BMO Capital Markets, BTIG Research, HC Wainwright, Jefferies Financial Group Inc., Royal Bank of Canada, and Wedbush.
View the latest analyst ratings for NUVB.

What is the current price target for Nuvation Bio?

5 Wall Street analysts have set twelve-month price targets for Nuvation Bio in the last year. Their average twelve-month price target is $4.00, suggesting a possible upside of 143.9%. Royal Bank of Canada has the highest price target set, predicting NUVB will reach $6.00 in the next twelve months. Jefferies Financial Group Inc. has the lowest price target set, forecasting a price of $2.00 for Nuvation Bio in the next year.
View the latest price targets for NUVB.

What is the current consensus analyst rating for Nuvation Bio?

Nuvation Bio currently has 3 hold ratings and 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe NUVB will outperform the market and that investors should add to their positions of Nuvation Bio.
View the latest ratings for NUVB.

What other companies compete with Nuvation Bio?

Other companies that are similar to Nuvation Bio include Khosla Ventures Acquisition, Tango Therapeutics, Erasca, 2seventy bio and Karyopharm Therapeutics. Learn More about companies similar to Nuvation Bio.

How do I contact Nuvation Bio's investor relations team?

Nuvation Bio's physical mailing address is 1500 BROADWAY SUITE 1401, NEW YORK NY, 10036. The company's listed phone number is 332-208-6102 and its investor relations email address is [email protected] The official website for Nuvation Bio is www.nuvationbio.com. Learn More about contacing Nuvation Bio investor relations.